Dietger W Niederwieser Selected Research

Imatinib Mesylate (Gleevec)

2/2008	Favorable long-term follow-up results over 6 years for response, survival, and safety with imatinib mesylate therapy in chronic-phase chronic myeloid leukemia after failure of interferon-alpha treatment.
4/2005	In chronic myeloid leukemia white cells from cytogenetic responders and non-responders to imatinib have very similar gene expression signatures.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Dietger W Niederwieser Research Topics

Disease

3	BCR-ABL Positive Chronic Myelogenous Leukemia (Chronic Myelogenous Leukemia) 07/2015 - 04/2005
2	Hodgkin Disease (Hodgkin's Disease) 05/2016 - 11/2008
2	Leukemia 07/2015 - 09/2014
1	Graft vs Host Disease (Graft-Versus-Host Disease) 07/2015
1	B-Cell Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia) 02/2014

Drug/Important Bio-Agent (IBA)

2	Imatinib Mesylate (Gleevec)FDA Link 02/2008 - 04/2005
1	Interferon-alpha (Interferon Alfa)IBA 02/2008
1	bcr-abl Fusion ProteinsIBA 02/2008

Therapy/Procedure

3	Stem Cell Transplantation 07/2015 - 02/2014
1	Induction Chemotherapy 05/2016
1	Drug Therapy (Chemotherapy) 05/2016
1	Transplantation 02/2014
1	Cell Transplantation 11/2008
1	Therapeutics 02/2008